Back to News
Market Impact: 0.3
Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP
Source: Nasdaq
Healthcare & BiotechProduct LaunchesCorporate Guidance & Outlook
Inovio Pharmaceuticals is approaching an October 30 PDUFA decision for INO-3107, its lead DNA medicine candidate for recurrent respiratory papillomatosis (RRP). The pending FDA action is a key binary catalyst for the company, with potential to materially affect INO shares depending on the approval outcome.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
INO0.35
PLTR-0.15
More News
- Goldman says these top tech stocks have plenty of upside ahead of earnings
- You Might Be Able to Invest in the Starlab Space Station -- but Should You?
- Biotech stocks are surging. How investors can play the new drug innovation boom
- Nvidia's role as AI financier faces first big test as neoclouds take market hit
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- Rick Lazio: We’ve lost an auto race before, China’s EV climb should worry us
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Selecting an AI Research Platform for Institutional Investors
- Weekly Update: New Reporting Features and More Sources for Document Search